Category Archives: Deals

Merck KGaA Acquires Sigma-Aldrich for $17 Billion

Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion. The purchase will expand the reach of Merck’s EMD Millipore chemical and equipment division, “increasing the company’s presence in North America and adding exposure to fast-growing Asian markets,” according to a press release from […]
Posted in Deals | Tagged , , , | Leave a comment

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Also posted in Emerging Markets, Europe, Global, Guest Blog, R&D, Strategy | Tagged , , | Leave a comment

Pharma & Biotech Most Active Sector in UK M&As

The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up. However M&A activity targeting the United Kingdom — standing at £37.5bn in H1 2014 — represented […]
Also posted in Europe | Tagged , , , , | Leave a comment

Medtech: Employment Up, Industry “Picking Up Steam”

Medtech employment remained steady in last year with most medical device makers experiencing an increase in their workforce, according to a new jobs report published by EP Vantage. Of the top 15 device makers, only three experienced a reduction in headcount and two of those were due to companies spinning off their respective pharmaceutical operations, […]
Also posted in Strategy, Technology | Tagged , , , , , | Leave a comment

Pharm Exec's 2014 Dealmakers Outlook

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast […]
Also posted in Global, Strategy | Tagged , , , | Leave a comment
  • Categories

  • Meta